Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat

Transplantation

Volumn 75, Issue 11, 2003, Pages 1881-1887

  Bilolo, Kupa K ^a   Ouyang, Jun ^a   Wang, Xiang ^a   Zhu, Shengyun ^a   Jiang, Wenlei ^a   Qi, Shijie ^a   Xu, Dasheng ^a   Hebert, Marie J ^a   Bekersky, Ihor ^b   Fitzsimmons, William E ^b   Chen, Huifang ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 2 CYANO N (4 CYANOPHENYL) 3 CYCLOPROPYL 3 OXOPROPIONAMIDE; FK 779; LEFLUNOMIDE; MALONONITRILAMIDE; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ALKYNES; ANIMALS; DRUG SYNERGISM; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MYOCARDIUM; NITRILES; RATS; RATS, INBRED ACI; RATS, INBRED BN; RATS, INBRED LEW; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037708567     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000064710.78335.D3     Document Type: Article

References (34)

1. Calne R, Collier DS, Thiru S. Observations about FK506 in primates. Transplant Proc 1987; 19(suppl 6): 63.
2. Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney and pancreas transplantation. Lancet 1989; 2: 100.
3. Woodle ES, Thistlethwaite JR, Gordon JH, et al. A multicenter trial of FK506 therapy in refractory acute renal allograft rejection. Transplantation 1996; 62: 594.
4. Metcalfe SM, Richards FM. Cyclosporine, FK506, and rapamycin. Transplantation 1990; 49: 798.
5. Vu MD, Qi S, Xu D, et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997; 64: 1853.
6. Chen H, Qi S, Xu D, et al. FK506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant Proc 1998; 30: 1039.
7. Qi S, Xu D, Peng J, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination-therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275.
8. Chen H, Peng J, Luo H, et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation 2000; 69: 1555.
9. McAlister VC, Peltekian K, Domingues J, et al. Sirolimus and tacrolimus combination immunosuppression. Lancet 2000; 355: 376.
10. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
11. Kurrle R, Bartlett RR, Ruuth E, et al. Malononitrilamides inhibit T- and B-cell responsiveness in different species. Transplant Proc 1997; 29: 1302.
12. Williams JW, Xao F, Forster P, et al. Leflunomide in experimental transplantation. Transplantation 1994; 57(8): 1223.
13. Qi Z, Ekberg H. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Scand J Immunol 1998; 48: 379.
14. Silva HT Jr, Helio T, Morris RE. Leflunomide and malononitrilamides. Am J Med Sci 1997; 313: 289.
15. Morris RE, Huang X, Gregory CR, et al. Studies in experimental models of chronic rejection: Use of rapamycin (sirolimus) and isoxazol derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1995; 27(3): 2068.
16. Schorlemmer HU, Barlett RR, Lindner JK, et al. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Transplant Proc 1998; 30: 4099.
17. Zhong R, He G, Saki Y, et al. The effect of donor-recipient strain combination on rejection and graft-versus-host disease after small bowel/liver transplantation in the rat. Transplantation 1993; 56: 381.
18. Chen H, Wu JP, Xu D, et al. Reversal of ongoing heart, kidney, and pancreas allografts rejection and suppression of accelerated heart allograft rejection in the rat by rapamycin. Transplantation 1993; 56: 661.
19. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
20. Fisher B, Lee S. Microvascular surgical techniques in research: With special reference to renal transplantation in the rat. Surgery 1965; 58: 904.
21. Billingham ME. Endomyocardial biopsy detection of acute rejection in cardiac allograft recipient. Heart Vessels Suppl 1985; 1: 86.
22. Berry GJ, Brunt EM, Chamberlain D, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 593.
23. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
24. Chou TC. The median-effect principle and combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout D, eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press 1991, p 61.
25. Stepkowski SM, Napoli KL, Wang ME, et al. Effects of the pharmacokinetic interaction between orally administered sirolimus on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62: 986.
26. Klintmalm GB. FK506: An update. Clin Transplant 1994; 8: 207.
27. Mladenovic V, Domljan Z, Rozman B, et at. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595.
28. Williamson RA, Yea CM, Robinson PA, et al. Dihydroorotate dehydrogenase, a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270: 22467.
29. Kahan BD. Immunosuppressive therapy. Curr Opin Immunol 1992; 4: 553.
30. Qi S, Zhu S, Xu D, et al. Significant prolongation of renal allograft survival by delayed combination of FK778 with tacrolimus in non-human primates. Transplantation (in press).
31. Vu MD, Qi S, Xu D, et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66: 1575.
32. Vu MD, Qi S, Wang X, et al. The combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays, and in rats receiving renal allografts. Transplantation (in press).
33. Jiang H, Sakuna S, Fujii Y, et al. Tacrolimus versus cyclosporin A: A comparative study on rat renal allograft survival. Transpl Int 1999; 12: 92.
34. Jiang H, Yang XF, Soriano R, et al. Inhibition of IL-10 by FK506 may be responsible for overcoming ongoing allograft rejection in the rat. Transplant Proc 1999; 31: 1203.